Decheng Capital
3000 Sand Hill RoadMenlo Park, CA 94025
Website: decheng.com
Firm Size
- Assets Under Management (AUM):$1.8 Billion
- Number of Funds:5
- Employees:21
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Decheng Capital LLC is a private equity firm based in Menlo Park, California. The company focuses on making investments in the life sciences and healthcare sectors, with a primary focus on companies engaged in research, development, and commercialization of innovative therapies and technologies. Decheng Capital aims to support these companies in their growth by providing both financial and strategic assistance. They typically invest in companies at various stages of development, from early-stage startups to established companies looking to expand their operations. The firm was founded in 2000 by Dr. Marek Biestek and Dr. Min Cui, who both have extensive experience in the biotechnology and healthcare industries. Decheng Capital raises funds from institutional investors and high-net-worth individuals and has built a strong track record of successful investments. In addition to providing capital, Decheng Capital leverages its network and industry expertise to help portfolio companies navigate various challenges and seize growth opportunities. They have a team of experienced professionals who actively engage with the management teams of their portfolio companies to provide guidance and support. Overall, Decheng Capital is known for its focus on the life sciences and healthcare sectors and its commitment to helping innovative companies reach their full potential through strategic investments and partnerships.Latest News
Powered by
May 09, 2024: Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing
Aardvark Therapeutics, Inc. announces an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Fitzgerald & Co., Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA , and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research.
Sep 25, 2023: Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach
Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman . Dr. Bratman will continue to serve as a member of Adela's Board of Directors and as President.
Aug 23, 2023: Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies
Apr 11, 2023: VintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene Therapies
VintaBio , a life sciences company with unmatched industry expertise helping alleviate the viral vector bottleneck in cell and gene therapy development, today emerged from stealth with newly appointed CEO David Radspinner at its helm, $64 million in funding led by Decheng Capital, and a custom-built manufacturing facility in Philadelphia that is open and accepting orders. VintaBio was founded by Junwei Sun and Dr. Shangzhen Zhou, who developed the first viral vectors used for life-saving therapies, including the cell therapy that cured Emily Whitehead of a pediatric cancer, as well as the first two FDA-approved gene therapies.